EJNMMI reports最新文献

{"title":"Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study.","authors":"Stephan Souza, Felipe Ribeiro, Ana Brito, Thaís Minekawa, Flávia Lopes, Sumara Matedi, Renata Fockink, Dalton Anjos, Gustavo Gomes, Laura Silva, Mariana Camacho, Allan Santos, Whemberton Araújo, Ana Teixeira, Raul Martins, Adelina Sanches, Nilton Hanaoka, Rafael Tavares, Felipe Villela-Pedras, Felipe Mourato, Caroline Torricelli, Thiago Alves, Marcelo Tavares, Mariana Lima, André Moraes, André Sasse, Paulo Almeida, Elba Etchebehere","doi":"10.1186/s41824-025-00245-9","DOIUrl":"https://doi.org/10.1186/s41824-025-00245-9","url":null,"abstract":"<p><strong>Background: </strong>Radium-223 (²²³Ra) therapy has been available since 2013 for metastatic castrate-resistant prostate cancer (mCRPC). However, only in 2017 ²²³Ra was approved by the National Health Surveillance Agency in Brazil. We aimed to perform a multicenter analysis of mCRPC patients treated with ²²³Ra in referral centers in Brazil and describe their clinical outcomes. For this reason, we retrospectively analyzed mCRPC patients who underwent ²²³Ra treatment. Clinical and laboratory data were evaluated.</p><p><strong>Results: </strong>308 patients submitted to 1402 ²²³Ra cycles from 9 centers were studied. Previous treatments prior to ²²³Ra were chemotherapy (59.1%), radiation therapy (54.8%) and hormone therapy (92.2%). ²²³Ra was used as the fifth or more line of treatment in 58.4% of the patients. The mean number of ²²³Ra cycles was 4.6; 51% of patients completed all 6 cycles and 52.9% progressed during ²²³Ra. Concomitant treatment with ²²³Ra occurred in 69.4% of patients. The median overall survival (OS) for all patients was 13.7 months. The OS was higher for patients completing 6 cycles compared to < 6 cycles (22.6 vs 6.4 months, respectively). When stratified according to Brazilian regions, the median OS for the southeast region was higher (range: 14.5-30.2 months) than the other regions.</p><p><strong>Conclusions: </strong>The OS of ²²³Ra for patients completing 6 cycles was very high. However, there were major discrepancies when stratified according to different regions in the nation. The data is an important demonstration of the country's educational referral discrepancies related to proper patient management for ²²³Ra therapy, which has a major impact on maximum OS benefit.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12018669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of amide proton transfer-weighted imaging and methionine positron emission tomography histogram parameters enhances the prediction of isocitrate dehydrogenase mutations in adult diffuse gliomas.","authors":"Masaoki Kusunoki, Takuro Isoda, Koji Yamashita, Yoshiyuki Kitamura, Kazufumi Kikuchi, Motohiro Sando, Shingo Baba, Daisuke Kuga, Yutaka Fujioka, Fumiya Narutomi, Koji Yoshimoto, Kousei Ishigami, Osamu Togao","doi":"10.1186/s41824-025-00248-6","DOIUrl":"https://doi.org/10.1186/s41824-025-00248-6","url":null,"abstract":"<p><strong>Background: </strong>To evaluate whether the combination of amide proton transfer-weighted imaging (APT-WI) and methionine positron emission tomography (MET-PET) enhances the non-invasive prediction of isocitrate dehydrogenase (IDH) mutation status in adult diffuse gliomas.</p><p><strong>Results: </strong>We retrospectively analysed 28 adult patients with histologically confirmed diffuse gliomas who underwent preoperative APT-WI and MET-PET imaging at our institution. Histogram analyses were conducted for both imaging modalities, extracting parameters such as the 10th, 50th, 70th, and 90th percentiles, mean, variance, skewness, and kurtosis. Parameters between IDH-mutant and IDH-wildtype gliomas were compared using the Mann-Whitney U test. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis, and combined models of the two parameters were constructed using multivariable logistic regression. IDH-wildtype gliomas exhibited significantly higher APT-WI 90th percentile (APT₉₀) values (median: 3.51%, interquartile range [IQR]: 1.92-4.23%) compared to IDH-mutant gliomas (median: 2.24%, IQR: 1.52-2.85%, p = 0.039). Similarly, IDH-wildtype gliomas showed elevated MET-PET maximum tumour-to-normal ratios (TNR_max) (median: 2.51, IQR: 2.13-3.41) compared to IDH-mutant gliomas (median: 1.62, IQR: 1.30-2.77, p = 0.020). ROC curve analysis indicated that the combined model of APT₉₀ and TNR kurtosis achieved an area under the curve of 0.85, demonstrating superior diagnostic accuracy compared to that of single-parameter models.</p><p><strong>Conclusions: </strong>Combining histogram-derived parameters from APT-WI and MET-PET significantly improves the diagnostic accuracy for predicting IDH mutation status in diffuse gliomas. This non-invasive approach may serve as a valuable adjunct for preoperative evaluation and the development of personalised treatment strategies in patients with gliomas.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11996729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medium-vessel vasculitis following COVID-19 moderna (mRNA-1273) vaccination and the utility of PET-CT as a diagnostic tool: a case report.","authors":"Martin H Cherk, Luigi Zolio, Sadid Khan, Sharmayne Brady","doi":"10.1186/s41824-025-00247-7","DOIUrl":"10.1186/s41824-025-00247-7","url":null,"abstract":"<p><p>There have been several case reports of COVID-19 \"BNT162b2\" (Pfizer-BioNTech) and \"mRNA-1273\" (Moderna) vaccination associated small and medium vessel vasculitis described in the literature however none have had ¹⁸F-FDG Positron Emission Tomography scans (PET/CT) performed for diagnosis. We report the case of a 57-year-old Caucasian male patient from Australia where ¹⁸F-FDG PET/CT scanning facilitated early detection of a medium-vessel vasculitis following Moderna (mRNA-1273) COVID-19 vaccination. The diagnosis would otherwise have been difficult and allowed exclusion of alternative diagnoses and sparing of more invasive investigations such as muscle biopsy. Our case highlights the development of a medium vessel vasculitis following mRNA based COVID-19 vaccination and demonstrates the utility of ¹⁸F-FDG PET/CT as an excellent non-invasive test for the detection of this serious rare and often difficult to diagnose condition.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic evaluation of [¹⁸F]fluorocholine PET/CT in pre operative assessment of hyperfunctional parathyroids in primary hyperparathyroidism: a cost effectiveness analysis.","authors":"Adel Mamou, Sihame Chkair, Olivier Gilly, Laurent Maimoun, Yassine Mamou, Sean C Sheppard, Pierre Olivier Kotzki, Benjamin Lallemant, Vincent Boudousq","doi":"10.1186/s41824-025-00244-w","DOIUrl":"10.1186/s41824-025-00244-w","url":null,"abstract":"<p><strong>Background: </strong>Primary hyperparathyroidism (PHPT) is characterized by persistent hypercalcemia caused by parathyroid adenomas. Preoperative localization of hyperfunctional parathyroids is crucial to optimize surgical outcomes. Current standard practice combines cervical ultrasound (CU), [^99mTc]Tc-sestaMIBI SPECT scintigraphy (MIBI), and [¹⁸F]Fluorocholine PET/CT (PET) centered on the cervico-thoracic region. This study evaluates the cost-effectiveness of PET as a stand-alone first-line imaging strategy compared to CU + MIBI + PET and CU + PET strategies in the French healthcare system.</p><p><strong>Methods: </strong>A Markov model estimated costs and quality-adjusted life years (QALYs) for each imaging strategy. Imaging performance parameters were derived from a cohort of 145 PHPT patients who underwent surgery after all three imaging exams. Costs were calculated from the perspective of the French healthcare system, and utilities were sourced from the literature and validated by experts. Probabilistic and deterministic sensitivity analyses assessed robustness, while a Budget Impact Analysis (BIA) evaluated financial implications of national adoption over three years (2025-2027).</p><p><strong>Results: </strong>The average costs per patient were €5175 for CU + MIBI + PET, €5406 for CU + PET, and €5320 for PET alone, with corresponding QALYs of 13.80, 13.81, and 13.82. PET alone had an incremental cost-effectiveness ratio (ICER) of €12,650/QALY and an incremental net monetary benefit (iNMB) of 855€ compared to CU + MIBI + PET but offered only marginal QALY gains (+ 0.02), which were not substantially different. Sensitivity analyses revealed PET alone becomes dominant if [99mTc]Tc-MIBI SPECT sensitivity falls below 75.5% or PET costs drop below €632.</p><p><strong>Conclusion: </strong>[¹⁸F]Fluorocholine PET/CT stand-alone could be a cost-effective option and considered as a first line imaging strategy. Imaging strategies should be adapted to local healthcare contexts, reimbursement models, and diagnostic performance to optimize cost-effectiveness and patient care.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capivasertib treatment associated with hypermetabolism of the spleen.","authors":"Maria Ly, Gary Z Yu, Amin Haghighat Jahromi","doi":"10.1186/s41824-024-00231-7","DOIUrl":"10.1186/s41824-024-00231-7","url":null,"abstract":"<p><p>Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143695066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supraclavicular nodal metastasis at primary staging of prostate cancer using ¹⁸F-PSMA-1007 PET/CT.","authors":"Samuel Nguku Gitau, Jasmit Shah, William Olwit, Samnakay Saeed, Manel Haj Mansour, Khalid Makhdomi","doi":"10.1186/s41824-025-00241-z","DOIUrl":"10.1186/s41824-025-00241-z","url":null,"abstract":"<p><strong>Background: </strong>The most common sites of metastasis in prostate cancer are bone, pelvic and retroperitoneal lymph nodes, liver and lungs. This study aimed to evaluate the prevalence of supraclavicular nodal metastasis in newly diagnosed prostate cancer using ¹⁸F-PSMA-1007 PET/CT which has hitherto been understudied.</p><p><strong>Methods: </strong>¹⁸F-PSMA-1007 PET/CT examinations performed at our institution between June 2020 and June 2022 for primary staging of prostate cancer were reviewed to identify supraclavicular nodal metastasis from prostate cancer. Data variables included age, stage of disease, PSA level, Gleason score and ISUP/WHO grade group and how these compare with the presence of supraclavicular nodal metastasis.</p><p><strong>Results: </strong>A total of 240 patients with prostate cancer staged with ¹⁸F-PSMA-1007 PET/CT were analyzed. More than half of the patients presented with stage IVA or IVB disease, 54.1% (n = 130/240), and with high or very high-risk disease, 74.6% (n = 179/240). The prevalence of supraclavicular nodal metastasis in this cohort was 7.9% (n = 19/240). Advanced stage and high-risk groups were strongly associated with the presence of supraclavicular nodal metastasis.</p><p><strong>Conclusion: </strong>There is moderate prevalence of supraclavicular nodal metastasis in patients with intermediate to very high-risk prostate cancer which has likely previously been underdiagnosed with conventional imaging and has been brought to the fore with new-generation imaging such as PSMA PET/CT. It should therefore be an area of consideration during diagnostic work up and follow up of prostate cancer patients. The prognostic significance of supraclavicular nodal metastasis in prostate cancer requires further research.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing large language models for Lugano classification of malignant lymphoma in Japanese FDG-PET reports.","authors":"Rintaro Ito, Keita Kato, Kosuke Nanataki, Yumi Abe, Hiroshi Ogawa, Ryogo Minamimoto, Katsuhiko Kato, Toshiaki Taoka, Shinji Naganawa","doi":"10.1186/s41824-025-00246-8","DOIUrl":"10.1186/s41824-025-00246-8","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluates the performance of four large language models (LLMs) in classifying malignant lymphoma stages using the Lugano classification from free-text FDG-PET reports in Japanese Specifically, we assess GPT-4o, Claude 3.5 Sonnet, Llama 3 70B, and Gemma 2 27B in their ability interpret unstructured radiology texts.</p><p><strong>Materials and methods: </strong>In a retrospective single-center study, 80 patients who underwent staging FDG-PET/CT for malignant lymphoma were included. The \"Findings\" sections of their reports were analyzed without pre-processing. Each LLM assigned Lugano stages based on these reports. Performance was compared to reference standard stages determined by expert radiologists. Statistical analyses involved overall accuracy, weighted kappa for agreement.</p><p><strong>Results: </strong>GPT-4o achieved the highest accuracy at 75% (60/80 cases) with substantial agreement (weighted kappa κ = 0.801). Claude 3.5 Sonnet had 61.3% accuracy (49/80, κ = 0.763). Gemma 2 27B and Llama 3 70B showed accuracies of 58.8% and 57.5%, respectively, all indicating substantial agreement.</p><p><strong>Conclusion: </strong>GPT-4o outperformed other LLMs in assigning Lugano classification from Japanese FDG-PET free-text reports. This demonstrated the potential of advanced LLMs to interpret clinical texts. While the immediate clinical utility of automatically predicting a Lugano stage from an existing report may be limited, these results highlight the value of LLMs for understanding and standardizing free-text radiology data.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143589206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of [¹⁸F]fluorodeoxyglucose and [⁶⁸Ga]Gallium DOTA-TATE in patients with active giant cell arteritis.","authors":"Alison H Clifford, Jonathan Abele, Ryan Hung, Frank Wuest, Jan Andersson, Susan Pike, Elaine Yacyshyn, Eric Lenza, Glen Jickling, Paolo Raggi, Jan Willem Cohen Tervaert","doi":"10.1186/s41824-025-00242-y","DOIUrl":"10.1186/s41824-025-00242-y","url":null,"abstract":"<p><strong>Purpose: </strong>[¹⁸F]Fluorodeoxyglucose (FDG) is widely used in PET/CT imaging to detect large vessel vasculitis in giant cell arteritis (GCA), but its performance is suboptimal in patients receiving glucocorticoids. We aimed to compare [⁶⁸Ga]Ga-HA-DOTA-TATE, a somatostatin 2-analogue tracer, to [¹⁸F]FDG in a pilot study of patients with GCA.</p><p><strong>Methods: </strong>Eight patients with active GCA were prospectively, sequentially scanned with both [¹⁸F]FDG PET/CT and [⁶⁸Ga]Ga-HA-DOTA-TATE PET/CT imaging. Images were evaluated by 2 blinded nuclear medicine specialists. Tracer uptake was assessed in 8 vascular territories using SUVmax, and target-background ratios (TBR) were calculated using both right atrium (TBR_RA) and liver mean (TBR_liver). Mean SUVmax and TBR of individual vascular territories and index vessels were compared.</p><p><strong>Results: </strong>The patient median age was 71.5 years (range 64-82), and 4 (50%) were women. Active vasculitis (≥ grade 2 visual uptake in large vessels) was present in 62.5% of [¹⁸F]FDG scans. [¹⁸F]FDG scans had higher RA background activity than [⁶⁸Ga]Ga-HA-DOTA-TATE (mean RA SUVmean 1.88 vs. 0.36, p < 0.001), while [⁶⁸Ga]Ga-HA-DOTA-TATE had a significantly higher liver uptake (mean liver SUVmean 7.54 vs. 2.39, p < 0.001). Vascular uptake (as measured by both SUVmax and TBR_liver) was significantly higher in [¹⁸F]FDG than [⁶⁸Ga]Ga-HA-DOTA-TATE scans in every vascular territory (p < = 0.05 for all comparisons), including index vessels (SUVmax 4.04 vs. 1.91, p = 0.01, TBR_liver 1.73 vs. 0.27, p < 0.001).</p><p><strong>Conclusion: </strong>In this pilot study of patients with active GCA, the arterial uptake of [⁶⁸Ga]Ga-HA-DOTA-TATE was lower and less conspicuous compared to [¹⁸F]FDG. While further evaluation in larger cohorts is needed, a clear advantage of [⁶⁸Ga]Ga-HA-DOTA-TATE over [¹⁸F]FDG for detecting vascular inflammation in GCA was not identified. TRIAL REGISTRATION, CLINICALTRIALS.GOV: NCT03812302, registered 2019-01-18, URL: https://clinicaltrials.gov/search?cond=dotatate%20%26;term=giant%20cell%20arteritis .</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective evaluation of the diagnostic accuracy of FDG-PET/CT for the detection of sternal wound infection post-sternotomy.","authors":"Angela Cai, Mehrshad Bakhshi, Yoan Lamarche, Francois Harel, Matthieu Pelletier-Galarneau","doi":"10.1186/s41824-024-00237-1","DOIUrl":"10.1186/s41824-024-00237-1","url":null,"abstract":"<p><strong>Purpose: </strong>Sternal wound infections (SWI) are complications of sternotomy and can be divided into deep SWI (DSWI) and superficial SWI (SSWI). In recent years, the use of 18F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in diagnosing infections and inflammation has expanded significantly, with a growing number of clinical indications. This study assesses FDG-PET/CT diagnostic role in DSWI detection, the evolution of FDG uptake intensity in patients without DSWI and the potential biomarkers for DSWIs prediction.</p><p><strong>Methods: </strong>We conducted a single center prospective study of consecutive patients referred for suspected SWI post-median sternotomy. Gold standard diagnosis was established by chart review of clinical follow-up, surgical findings, and cultures. To characterize the time between sternotomy and imaging, participants were subsequently subdivided into recent (< 3 months) or remote surgery (≥ 3 months) groups.</p><p><strong>Results: </strong>44 FDG-PET/CT scans, 12 (27%) of which had DSWI according to the gold standard, were collected and analyzed. 20 studies were assigned to the recent group, and 24 studies to the remote surgery group. Sensitivity and specificity of FDG-PET/CT for detection of DSWI were 67% and 66%, respectively and an accuracy of 66% was obtained. Positive and negative predictive values were 42% and 84%, respectively. The NPV was higher in the remote surgery group (100%) compared to the recent surgery group (73%). SUV_max of the median sternal wound was significantly higher in the DSWI (9.3 ± 2.3) than the non-DSWI group (7.1 ± 3.0) (p = 0.025). There was however significant overlap of SUV_max between the two groups. CRP, WBC counts, and PCT levels were not significantly different between the DSWI and non-DSWI groups (p ≥ 0.34).</p><p><strong>Conclusion: </strong>FDG-PET/CT has modest sensitivity and specificity for the detection of DSWI post-sternotomy. FDG-PET/CT results must take into account time since surgery; when PET/CT is performed more than 3 months following surgery, a negative scan can exclude DSWI with a high level of certainty.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11806163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143371462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of delayed pelvic imaging on the staging of biochemical recurrence in prostate cancer patients using [¹⁸F]DCFPYL PET/CT: a retrospective evaluation.","authors":"Ana Rodríguez-Pajuelo, Miriam Guerra-Gómez, Juan Ignacio Cuenca Cuenca, José María Freire-Macías, José Manuel Jiménez-Hoyuela García, Rosa María Álvarez-Pérez","doi":"10.1186/s41824-025-00238-8","DOIUrl":"10.1186/s41824-025-00238-8","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to evaluate the added diagnostic value of additional second stage pelvic scanning as part of the [¹⁸F]DCFPYL PET/CT procedure in patients treated for prostate cancer (PCa) who have biochemical recurrence (BR).</p><p><strong>Materials and methods: </strong>Consecutive patients with a diagnosis of PCa who underwent a dual-phase PSMA-PET scan between September 2022 and December 2023, were retrospectively included. We analyzed the number and maximum SUV (SUVmax) of lesions only in the pelvic region (prostate, locoregional lymph nodes and bone), based on PSMA-RADS version 2.0 and miTNM criteria. To assess the potential diagnostic benefit of additional delayed pelvic PET/CT imaging as part of the PSMA-PET procedure, the change in molecular TNM classification was evaluated after the procedure.</p><p><strong>Results: </strong>Additional delayed pelvic PET/CT imaging as part of the PSMA-PET procedure resulted in a change in molecular TNM classification in 22 out of 136 patients (16.2%). The highest percentage change was obtained in the miN classification (14/22 patients), followed by the miT classification (7/22) and lastly miM (1/22). Moreover, we found that patients in whom delayed pelvic imaging resulted in a change in molecular TNM classification were significantly older and had a higher PSA level than those in whom delayed imaging did not provide additional information.</p><p><strong>Conclusions: </strong>Pelvic delayed imaging in patients with biochemical recurrence of prostate cancer undergoing PET/CT with [¹⁸F]DCFPYL shows a non-negligible influence on patient staging, modifying the miTNM classification in 16.2% of cases, with pelvic lymphatic involvement benefiting the most from the dual study.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}